Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PHP with or without ipilimumab + nivolumab for metastatic uveal melanoma
NL-OMON52669Phase 2Recruiting
- Sponsor
- Leiden University Medical Center
- Start
- Dec 2019
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial in intraocular melanoma and eye melanoma comparing PHP alone with PHP + ipilimumab + nivolumab (2 arms). Primary endpoints: Safety and tolerability, Dose-limiting toxicities and 3 more. Started Dec 2019; status: recruiting.
02
Drugs
03
Conditions
intraocular melanomaeye melanoma
Beyond the preview
Go deeper on NL-OMON52669.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON52669.